Angeion Corporation (NASDAQ: ANGN) announced today that efforts to extend and enhance its commitment to sell and market MedGraphics’ non-invasive cardiorespiratory diagnostic systems to the clinical device and drug trial research market are having significant results. These results include the recent execution of new agreements under which the Company will supply its diagnostic systems and services to third parties conducting clinical studies. Angeion believes sales to these third parties for clinical studies have the potential to result in revenue increases approaching 5-10% of Angeion’s MedGraphics cardiorespiratory products. Terms of the recent agreements are confidential.
